Breast Cancer Pipeline Accelerates as 250+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight's "Breast Cancer Pipeline Insight 2026" report provides comprehensive insights about 250+ Breast Cancer companies and 300+ pipeline drugs in the Breast Cancer pipeline landscape. It covers the Breast Cancer pipeline drugs profiles, including clinical and nonclinical stage products. It also covers the Breast Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Breast Cancer Pipeline @ https://www.delveinsight.com/sample-request/breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Breast Cancer Pipeline Report
• On July 20, 2026- Merck Sharp & Dohme LLC initiated a phase 3 study is to compare sacituzumab tirumotecan as a single agent, and in combination with pembrolizumab, versus Treatment of Physician's Choice (TPC) in participants with hormone receptor positive/human epidermal growth factor receptor-2 negative (HR+/HER2-) unresectable locally advanced, or metastatic, breast cancer.
• On July 17, 2026- BioNTech SE conducted a Phase III trial where participants will be randomized to two treatment groups, which means participants will be assigned by equal chance to a treatment group. This trial will be double-blinded, which means neither the participants nor the trial doctors will know which of the two treatments the participants actually receive. Participants will receive either the trial drug with chemotherapy or placebo (which looks like the trial drug but does not have any drug in it) with chemotherapy.
• On July 17, 2026- Eli Lilly and Company a phase 2 study will include two groups of patients: Cohort 1 and Cohort 2. Some patients will take both imlunestrant and another treatment to suppress their ovarian function. Some will take it without ovarian suppression.
• DelveInsight's Breast Cancer pipeline report depicts a robust space with 250+ Breast Cancer companies working to develop 300+ pipeline therapies for Breast Cancer treatment.
• The leading Breast Cancer Companies such as Tanvex Biopharma, Sichuan Kelun-Biotech Biopharmaceutical, Shanghai Henlius Biotech, Byondis, CSPC Ouyi Pharmaceutical Co., Ltd., Pfizer, Jazz Pharmaceuticals, Biostar Pharma, Inc., Chia Tai Tianqing Pharmaceutical Group, InventisBio, Coherent Biopharma, Shanghai Jiaolian Drug Research and Development Co., Ltd., Ambrx, MediLink Therapeutics (Suzhou) Co., Ltd., Tasly Pharmaceutical Group, Convalife (Shanghai) Co., Ltd., Merck & Co., AstraZeneca, Aclaris Therapeutics, Boehringer Ingelheim, NovaOnco Therapeutics Co., Ltd., Verastem Oncology, Ellipses Pharma, Shenzhen Yangli Pharmaceutical Technology Co., Ltd., TYK Medicine, Ascendis Pharma, ExpreS2ion Biotechnologies, Mersana Therapeutics, Exelixis, Shenzhen Celconta Life Science, Beijing Wehand-Bio Pharmaceutical, VM Oncology, Hinova Pharmaceuticals, OS Therapies, and Syntab Therapeutics and others.
• Promising Breast Cancer Pipeline Therapies such as Oraxol, ARV-471, Ribociclib, E7389, Trastuzumab, GM-CSF, GM-CSF, Trastuzumab, Paclitaxel, Gemcitabine/Carboplatin, Iniparib, and others.

Stay ahead with the most recent pipeline outlook for Breast Cancer @ https://www.delveinsight.com/sample-request/breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

The Breast Cancer Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Breast Cancer Pipeline Report also highlights the unmet needs with respect to the Breast Cancer.

Breast Cancer Overview
Breast cancer is a malignant tumor that originates in the cells of the breast, most commonly in the ducts (ductal carcinoma) or lobules (lobular carcinoma). It is one of the most prevalent cancers among women worldwide, although it can also occur in men. Risk factors include age, family history, genetic mutations such as BRCA1 and BRCA2, hormonal factors, obesity, and lifestyle choices. Breast cancer can range from localized, slow-growing tumors to aggressive types that metastasize to other parts of the body.

Breast Cancer Emerging Drugs Profile
• Vepdegestrant (ARV-471): Pfizer/ Arvinas
Vepdegestrant is an investigational, orally bioavailable PROteolysis TArgeting Chimera (PROTAC) protein degrader designed to specifically target and degrade the estrogen receptor (ER) for the treatment of patients with ER-positive (ER+)/human epidermal growth factor receptor 2 (HER2)-negative (ER+/HER2-) breast cancer. Vepdegestrant is being developed as a potential monotherapy for ER+/HER2- advanced or metastatic breast cancer with estrogen receptor 1 (ESR1) mutations in the second line-plus setting. The U.S. Food and Drug Administration (FDA) has granted vepdegestrant Fast Track designation as a monotherapy in the treatment of adults with ER+/HER2- advanced or metastatic breast cancer previously treated with endocrine-based therapy. Currently the drug is in Preregistration stage of development for the treatment of ER+/HER2- Metastatic Breast Cancer, ER+/HER2- Early Breast Cancer.

• Utidelone: Biostar Pharma, Inc.
Utidelone (UTD1), developed by Biostar Pharma, is a genetically engineered epothilone analog and next-generation microtubule inhibitor that received approval in China in March 2021 for metastatic breast cancer. Unlike taxanes, it binds a different site on microtubules, enabling it to overcome taxane resistance, demonstrate strong antitumor activity, and maintain low hematologic toxicity-showing both progression-free survival (PFS) and overall survival (OS) benefits in heavily pretreated patients when combined with capecitabine. Ongoing global trials include expanding indications such as neoadjuvant breast cancer, brain metastases, and even oral formulations to enhance convenience and broaden therapeutic impact. Currently the drug is in Phase III stage of development for the treatment of advanced breast cancer, Breast cancer neoadjuvant and breast cancer brain metastasis.

• ARX788: Ambrx, Inc.
ARX788, an anti-HER2 ADC currently being studied broadly in breast cancer, gastric/GEJ cancer and other solid tumor clinical trials. ARX788 is a homogeneous and highly stable ADC, which targets the HER2 receptor and contains two AS269 cytotoxic payloads site-specifically conjugated to a trastuzumab-based antibody. ARX788 was designed to maximize potential anti-tumor activity by optimizing the number and position of the payloads and the chemical bonds that conjugate the payloads to the antibody. AS269, proprietary payload, is a tubulin inhibitor specifically designed to form a highly stable covalent bond with our SAAs and kill tumor cells only upon entry into the cell when aided by the conjugated targeting antibody, thereby limiting off-target effects on healthy tissue. Currently, the drug is in the Phase II/III stage of its development for the treatment of Triple Negative Breast Cancer.

• TSL-1502: Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.
TSL-1502 is a pro-drug and its metabolite TSL-1502M has higher localized concentration at cancer sites with more potency, thus, our preclinical studies demonstrated that TSL-1502's anticancer activity is superior to competitor(s) while having a much wider therapeutic window. TSL-1502 is a small molecule drug, ready for clinical investigation (INDs) under both Chinese FDA (cFDA) and US FDA regulations. A phase II clinical trial will be managed and conducted in the USA. TSL-1502 is positioned to have strong PCT patent protections. Patents cover chemical structure, chiral auxiliary structures, crystal form, synthesize methods, and all potential indications. Currently the drug is in Phase II stage of its development for the treatment of HER2-negative Locally Advanced or Metastatic Breast Cancer Patients With Germline BRCA Mutations.

• PF-07104091: Pfizer
PF-07104091, also known as tegtociclib, is a first-in-class, orally administered, selective CDK2 inhibitor being developed for the treatment of various advanced solid tumors, with a particular focus on hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer that has progressed after prior CDK4/6 inhibitor therapy. By selectively inhibiting CDK2, PF-07104091 aims to induce cell cycle arrest through reduced phosphorylation of retinoblastoma protein (Rb) and other downstream targets, offering a novel approach to overcoming resistance to existing CDK4/6 inhibitors. Early-phase clinical trials have demonstrated that PF-07104091 is generally well tolerated and shows preliminary antitumor activity in heavily pretreated patients, with ongoing studies evaluating its use both as monotherapy and in combination with other agents such as fulvestrant and palbociclib. Currently, the drug is in the Phase II stage of its development for the treatment of Breast Cancer.

• XL092: Edgewood Oncology Inc.
XL092 is a third-generation oral tyrosine kinase inhibitor that inhibits the activity of receptor tyrosine kinases implicated in cancer growth and spread, including VEGF receptors, MET, AXL and MER. These receptor tyrosine kinases are involved in both normal cellular function and in pathologic processes such as oncogenesis, metastasis, tumor angiogenesis and resistance to multiple therapies, including immune checkpoint inhibitors. Zanzalintinib is currently being developed for the treatment of advanced solid tumors, including genitourinary, colorectal and head and neck cancers. The drug is currently being evaluated under Phase I/II stage of development for the treatment of patients suffering from breast cancer.

Explore groundbreaking therapies and clinical trials in the Breast Cancer Pipeline @ https://www.delveinsight.com/sample-request/breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Breast Cancer Companies
Tanvex Biopharma, Sichuan Kelun-Biotech Biopharmaceutical, Shanghai Henlius Biotech, Byondis, CSPC Ouyi Pharmaceutical Co., Ltd., Pfizer, Jazz Pharmaceuticals, Biostar Pharma, Inc., Chia Tai Tianqing Pharmaceutical Group, InventisBio, Coherent Biopharma, Shanghai Jiaolian Drug Research and Development Co., Ltd., Ambrx, MediLink Therapeutics (Suzhou) Co., Ltd., Tasly Pharmaceutical Group, Convalife (Shanghai) Co., Ltd., Merck & Co., AstraZeneca, Aclaris Therapeutics, Boehringer Ingelheim, NovaOnco Therapeutics Co., Ltd., Verastem Oncology, Ellipses Pharma, Shenzhen Yangli Pharmaceutical Technology Co., Ltd., TYK Medicine, Ascendis Pharma, ExpreS2ion Biotechnologies, Mersana Therapeutics, Exelixis, Shenzhen Celconta Life Science, Beijing Wehand-Bio Pharmaceutical, VM Oncology, Hinova Pharmaceuticals, OS Therapies, and Syntab Therapeutics and others.

Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Breast Cancer Products have been categorized under various molecular types such as
• Monoclonal antibody
• Small molecule
• Peptide

Learn about new drugs, pipeline developments with DelveInsight's expert analysis @ https://www.delveinsight.com/sample-request/breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Breast Cancer Pipeline Report
• Coverage- Global
• Breast Cancer Companies- Tanvex Biopharma, Sichuan Kelun-Biotech Biopharmaceutical, Shanghai Henlius Biotech, Byondis, CSPC Ouyi Pharmaceutical Co., Ltd., Pfizer, Jazz Pharmaceuticals, Biostar Pharma, Inc., Chia Tai Tianqing Pharmaceutical Group, InventisBio, Coherent Biopharma, Shanghai Jiaolian Drug Research and Development Co., Ltd., Ambrx, MediLink Therapeutics (Suzhou) Co., Ltd., Tasly Pharmaceutical Group, Convalife (Shanghai) Co., Ltd., Merck & Co., AstraZeneca, Aclaris Therapeutics, Boehringer Ingelheim, NovaOnco Therapeutics Co., Ltd., Verastem Oncology, Ellipses Pharma, Shenzhen Yangli Pharmaceutical Technology Co., Ltd., TYK Medicine, Ascendis Pharma, ExpreS2ion Biotechnologies, Mersana Therapeutics, Exelixis, Shenzhen Celconta Life Science, Beijing Wehand-Bio Pharmaceutical, VM Oncology, Hinova Pharmaceuticals, OS Therapies, and Syntab Therapeutics and others.
• Breast Cancer Pipeline Therapies- Oraxol, ARV-471, Ribociclib, E7389, Trastuzumab, GM-CSF, GM-CSF, Trastuzumab, Paclitaxel, Gemcitabine/Carboplatin, Iniparib, and others.
• Breast Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Breast Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Breast Cancer Therapies and clinical trials @ https://www.delveinsight.com/sample-request/breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Introduction
2. Executive Summary
3. Breast Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Breast Cancer- DelveInsight's Analytical Perspective
7. Late Stage Products (Registration)
8. Vepdegestrant (ARV-471): Pfizer/ Arvinas
9. Mid Stage Products (Phase II)
10. PF-07104091: Pfizer
11. Early Stage Products (Phase I/II)
12. XL092: Edgewood Oncology Inc.
13. Preclinical and Discovery Stage Products
14. Drug Name: Company Name
15. Inactive Products
16. Breast Cancer Key Companies
17. Breast Cancer Key Products
18. Breast Cancer- Unmet Needs
19. Breast Cancer- Market Drivers and Barriers
20. Breast Cancer- Future Perspectives and Conclusion
21. Breast Cancer Analyst Views
22. Breast Cancer Key Companies
23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.